Condition: Chronic Pulmonary Aspergillosis · Allergic Bronchopulmonary Aspergillosis · Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh
While ABPA and CPA represent two distinct manifestations of Aspergillus-related lung disease, there is an overlap of investigations that are currently used for the diagnosis of these entities. In a previous study, the authors have demonstrated that 22% of subjects with CPA fulfilled the obligatory criteria for ABPA. While the preferable therapy in patients with ABPA is systemic glucocorticoids, the primary therapy in CPA is oral triazoles. However, a different management protocol in the "overlap group" with low doses of glucocorticoids and triazoles, needs to be systematically explored. In this study the investigators intend to compare the clinical outcomes in subjects with ABPA-CPA overlap treated either with oral azoles or a combination of systemic glucocorticoids and oral azoles.
This description comes directly from the study's public registry record.
Inderpaul S Sehgal, MD, DM · 91-172275 · inderpgi@outlook.com
Ritesh Agarwal, MD,DM · 91-172275 · agarwal.ritesh@outlook.in
Always discuss trial participation with your own doctor first.
| Chest clinic | Chandigarh, Chandigarh, India | Recruiting |
| Chest clinic, PGIMER | Chandigarh, India | Active Not Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05444946